Atul Dandekar Sells 7,500 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at approximately $717,675. This represents a 22.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Trading Down 2.6%

NASDAQ:MAZE opened at $26.92 on Friday. The company’s 50 day moving average is $27.36 and its 200-day moving average is $34.05. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a 12 month low of $12.81 and a 12 month high of $53.65. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -10.64 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. Equities analysts anticipate that Maze Therapeutics, Inc. will post -2.73 EPS for the current year.

Hedge Funds Weigh In On Maze Therapeutics

Large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its stake in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after buying an additional 2,390,713 shares during the period. Vanguard Group Inc. grew its position in Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after buying an additional 915,342 shares in the last quarter. Marshall Wace LLP increased its stake in Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after acquiring an additional 758,104 shares during the period. Caligan Partners LP acquired a new position in Maze Therapeutics in the 4th quarter valued at approximately $22,794,000. Finally, Squadron Capital Management LLC acquired a new position in Maze Therapeutics in the 4th quarter valued at approximately $20,301,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Truist Financial lowered their price target on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.